Combination of Pembrolizumab and Lenvatinib, in Pre-treated Thymic CArcinoma paTIents

Summary

This is a multicentric, open-label, single arm phase II study to evaluate the efficacy and safety of the combination of pembrolizumab and lenvatinib in pre-treated thymic carcinoma patients who have progressed after at least one line of platinum-based chemotherapy for advanced disease without having received any previous immunotherapy (previous bevacizumab allowed, but not sunitinib), and not amenable to curative-intent radical surgery and/or radiotherapy, regardless of PD-L1 status.

Timeline

Start

2021-09-21

Primary completion

2024-07-01

Completion

2026-02-16

Outcome

Met primary endpoint

paper the study met its primary endpoint, with 5-month progression-free survival of 88·4% (90% CI 79·8-96·7). PMID 40907517 ↗

Publications

• Remon J, Bironzo P, Girard N, Bigay-Game L, Juan-Vidal O, de Castro J, Reguart N, Greillier L, Cousin S, Dansin E, Majem M, Bernabe R, Mosquera Martinez J, Diaz M, Meya A, Alcala-Lopez D, Garcia-Sanz A, Righi L, Novello S, Besse B. Lenvatinib plus pembrolizumab in pretreated metastatic B3 thymoma and thymic carcinoma (PECATI): a single-arm, phase 2 trial. Lancet Oncol. 2025 Sep;26(9):1215-1226. doi: 10.1016/S1470-2045(25)00300-6.

Drugs

Indications